What is heartburn worth? A cost-utility analysis of management strategies

Journal of General Internal Medicine

Volumn 15, Issue 3, 2000, Pages 175-182

  Heudebert, Gustavo R ^a,c   Centor, Robert M ^a   Klapow, Joshua C ^a,c   Marks, Robert ^b   Johnson, Lawrence ^b   Wilcox, C Mel ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cost utility analysis; Heartburn; Histamine2 receptor antagonist; Proton pump inhibitor; Quality of life

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEARTBURN; HUMAN; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TREATMENT PLANNING;

ANTI-ULCER AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; DIGESTIVE SYSTEM; DISEASE MANAGEMENT; ENDOSCOPY, DIGESTIVE SYSTEM; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; PROTON PUMPS; QUALITY-ADJUSTED LIFE YEARS; RADIOGRAPHY, ABDOMINAL; SENSITIVITY AND SPECIFICITY;

EID: 0034098636     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.2000.02639.x     Document Type: Article

References (42)

1. Richter JE. Long term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol. 1997;92(4): 30S-35S.
2. DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med. 1995; 155(13):2165-73.
3. Heading RC. Epidemiology of esophageal reflux disease. Scand J Gastroenterol. 1989;24(suppl 168):33-7.
4. Howden CW, Castell DO, Cohen S, et al. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intern Med. 1995;155:1465-71.
5. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995; 333(17):1106-10.
6. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994;121(3):161-7.
7. Robinson M, Lanza F, Avner D, et al. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. Ann Intern Med. 1996;124(10):859-67.
8. Johnsson F, Joelsson B, Gudmundsson K, et al. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol. 1987;22:714-8.
9. Johnston BT, McFarland RJ, Collins JSA, et al. Symptom index as a marker of gastro-oesophageal reflux disease. Br J Surg. 1992;79:1054-5.
10. Singh S, Richter JE, Bradley LA, et al. The symptom index: Differential usefulness in suspected acid-related complaints of heartburn and chest pain. Dig Dis Sci. 1993;38(8):1402-8.
11. Sox HC, Blatt MA, Higgins MC, et al. In: Medical Decision Making. Stoneham, Mass: Butterworths Publishing; 1988.
12. Gold MR, Siegel JE, Russell LB, et al. In: Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Publishing; 1996.
13. Spiro HM. Clinical Gastroenterology. 4th Ed. New York, NY: McGraw-Hill; 1993.
14. Thompson JK, Koehler RE, Richter JE. Detection of gastroesophageal reflux: value of barium studies compared with 24-hr pH monitoring. AJR. 1994;162:621-6.
15. Ott DJ. Gastroesophageal reflux: what is the role of barium studies? AJR. 1994;162(3):627-9.
16. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med. 1998;158:2373-6.
17. Joelsson B, Johnsson F. Heartburn - the acid test. Gut. 1989; 30: 1523-5.
18. Dehn TC, Shepard HA, Colins-Jones D, et al. Double blind comparison of omeprazole (40mg qd) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut. 1990;31:509-13.
19. Klinkenberg EC, Jansen JM, Festen HP, et al. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet. 1987;349-51.
20. Vantrappen G, Rutgeerts L, Schurmans P, et al. Omeprazole (40mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci. 1988;33(5):523-9.
21. Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis: results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol. 1988;23:625-32.
22. Hatlebakk J, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis: results of a Scandinavian multicentre trial. Scand J Gastroenterol. 1993; 28:224-8.
23. Hetzel D, Dent J, Reed W, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903-12.
24. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. Multicenter Study. Gastroenterology. 1992;102:109-18.
25. Dent J, Hetzel DJ, Hetzel MA, et al. Evaluation of omeprazole in reflux oesophagitis. Scand J Gastroenterol. 1989;24(suppl 166): 76-82.
26. 2-receptor antagonist therapy: lansoprazole, a new proton pump inhibitor. Dig Dis Sci. 1995; 40(3):590-7.
27. 2-receptor antagonist with lansoprazole, a new H+/K+-ATPase inhibitor: a controlled, double-blind study. Am J Gastroenterol. 1993;88(8):1212-7.
28. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Ailment Pharmacol Ther. 1996;10:529-39.
29. Dent J, Yeomans N, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis: a controlled double blind trial of their efficacy and safety. Gut. 1994;35:590-8.
30. Lundell L, Backman L, Ekstrom P, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol. 1991;26:248-56.
31. Lundell L. Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Digestion. 1990;47(suppl 1):72-5.
32. Lind T, Havelund R, Carlsson R., et al. Effect of omeprazole (OME) 20 mg and 10 mg daily on heartburn in patients with endoscopy negative reflux disease (ENRD) treated on an on demand basis. Gastroenterology. 1996;110(suppl 6):A178.
33. Soll AH. Medical treatment of peptic ulcer disease. JAMA. 1996;275:622-9.
34. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995;333:984-91.
35. Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastrooesophageal reflux disease. Gut. 1992;33:118-24.
36. Feinstein AR. Clinimetrics. New Haven, Conn: Yale University Press; 1987.
37. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
38. Drug Topics Red Book. Montvale, NJ: Medical Economics: 1996.
39. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analyses using Monte Carlo simulation. Med Decis Making. 1985;5:157-77.
40. Harris RA, Kupperman M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am J Med. 1997;102:78-88.
41. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, Mass: The Health Institute, New England Medical Center; 1993.
42. Sonnenberg A, Delco F, El-Serag H. Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis. Dig Dis Sci. 1998;43:1001-8.